Our commitment to fostering a culture of open communication and collaboration is exemplified through our annual global engagement survey results. This year's participation rate remained high at 95%, reflecting the Executive Leadership Team's commitment to valuing employee feedback and taking action. The overall engagement score was 8.3, positioning ALK in the top 5% against the international healthcare benchmark.
Health and safety management is an essential part of ALK’s operations, especially in production and farming activities where employees may face workplace risks.
1 2022 and 2023 figures are not covered by the Independent Auditor’s limited assurance report on the Sustainability Statement
Embracing a multi-dimensional perspective, we acknowledge diversity in terms of physical, psychological, social, lifestyle, and cognitive dimensions, actively engaging with a number of employee focus groups to seek input on improving inclusion across ALK. Furthermore, ALK tracks employees’ perceptions of diversity and inclusion and their sense of psychological safety via the annual employee engagement survey. In 2024, the overall perception of D&I in ALK is 8.4, which is 0.2 points above the industry benchmark.
Recognising the pivotal role of development in enhancing employee retention and performance, ALK seeks to foster a culture of continuous learning and growth for its workforce. Development agreements are integrated as a fundamental component of our annual people processes for all employees to gain a clear direction for their learning and growth opportunities as part of the Global People Performance Process.
ALK's Third-party Code of Conduct outlines the standards of behavior that we expect from all third parties globally when it comes to business conduct and treatment of employees. The Third-party Code of Conduct is an integrated part of our GxP (good practice) supplier agreements.
To address supplier risk, we utilize an external supplier evaluation platform to identify environment, labor & human rights, and procurement risks. 400+ suppliers approved for our GxP processes have been screened, none of which have been identified as high-risk.
Helping more people with allergies is at the core of ALK. We aim to support 5 million allergy patients by 2030 to advance our positive impact. In 2024, ALK reached an estimated 2.6 million patients in treatment, as a result of its commercial activities.
1Due to the lack of comprehensive data across all markets, directly measuring the number of patients treated with ALK products is not possible. Estimates are made using various data sources, an in-house Patient Model, and insurance claims data, but this involves assumptions that introduce uncertainty. The use of this datapoint is considered significant.
Social inclusion of consumers and end-users
With over 500 million people worldwide affected by respiratory allergies, many suffer without adequate support and treatment options. We wish to improve access to clinically proven allergy diagnosis and treatment solutions, ultimately improving the lives of allergy sufferers globally. As part of our efforts to ensure inclusivity and accessibility of our allergy medicines, we are prioritising two key areas: extending our geographical reach and obtaining approvals for children and adolescents.
Conducting clinical trials
In our ongoing efforts to develop innovative treatments for allergies, our clinical trials uphold safety, privacy, ethics and respect.
We adhere to:
• the European Federation of Pharmaceutical Industries and Associations (EFPIA)
• the Pharmaceutical Research and Manufactures of America (PhRMA) Principles for Responsible Clinical Trial Data Sharing.
ALK has a rigorous safety reporting system in place ensuring that safety data from any source, including clinical trials, are collected and analysed systematically by our global pharmacovigilance team. This ensures that the safety profile of our products is optimized for the benefit of users, and that the relevant authorities can be made aware of any safety issue arising from our products to facilitate immediate action.
We engage systematically in educational activities, training and dialogue with healthcare professionals to elevate the standard of care in allergy diagnosis and treatment. Much of our engagement is done digitally enabling us to reach more healthcare professionals and reduce our climate impact.
Social